Current Consulting Group

Alcohol remains one of the most significant—and often overlooked—workplace safety risks. During Alcohol Awareness Week, learn why now is the perfect time to review your organization's drug and alcohol policy, supervisor training, and impairment response procedures. Do you have any questions? Contact the Current Consulting Group at: [email protected].

Alcohol Awareness Week 2026: Why Employers Shouldn't Overlook Alcohol in Their Workplace Drug and Alcohol Program Alcohol Awareness Week 2026: Why Employers Shouldn’t Overlook Alcohol in Their Workplace Drug and Alcohol Program This information is provided for educational purposes only. Reader retains full responsibility for the use of the information contained herein.   Each year, Alcohol Awareness Week enc...

Register to attend a webinar on Wednesday, July 15, 2026 at 1:00 p.m. ET, sponsored by Abbott, and learn about - ​Ma*****na Rescheduling and Oral Fluid Testing: What Employers Should Know. Save your seat here: https://register.gotowebinar.com/register/8945685333954059605

From building meaningful relationships to experiencing new technologies firsthand, in-person engagement offers insights that simply can’t be replicated online. Attending NDASA's Annual Conference & Trade Show helps professionals stay ahead of evolving trends, regulations, and best practices shaping the drug and alcohol screening industry.

Stop by Booth 207 to say hello to Jessica Polk and Vince Bonomo. Additionally, CCG will host presentations on Tuesday and Wednesday, including a session highlighting the results of the 2026 Drug Testing Industry Survey. We hope to see you there!

Why We Attend NDASA’s Annual Conference: Connections, Technology, Trends Why We Attend NDASA’s Annual Conference: Connections, Technology, Trends This information is provided for educational purposes only. Reader retains full responsibility for the use of the information contained herein. Why We Attend NDASA’s Annual Conference: Connections, Technology, Trends There....

On April 23, 2026, the federal government moved FDA-approved and state-licensed ma*****na products from Schedule I to Schedule III. While this change is being celebrated in some circles, it raises serious questions about consistency, safety, and what this means for the workplace.

This article breaks down what this decision actually does—and just as importantly, what it doesn’t do. From workplace drug testing policies to the risks of employee impairment in safety-sensitive roles, the implications are significant. Click to read more.
https://currentconsultinggroup.com/ma*****na-officially-now-a-schedule-iii-drug-whats-next/

*****na

Ma*****na Officially Now a Schedule III Drug: What’s Next? Ma*****na Officially Now a Schedule III Drug: What’s Next? This information is provided for educational purposes only. Reader retains full responsibility for the use of the information contained herein. April 23, 2026: Today, Acting Attorney General Todd Blanche signed an order rescheduling “FDA...